Summary of Study ST000218

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000160. The data can be accessed directly via it's Project DOI: 10.21228/M8JG6Z This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST000218
Study TitleRole of Microbiome in Psoriatic Arthritis (SCFA in PsA)
Study TypeShort-chain fatty acid analysis
Study SummaryTo characterize the diversity and taxonomic relative abundance of the gut microbiota in patients with never-treated, recent-onset psoriatic arthritis (PsA). Methods High-throughput 16S ribosomal RNA pyrosequencing was utilized to compare the community composition of gut microbiota in patients with PsA (n = 16), patients with psoriasis of the skin (n = 15), and healthy, matched control subjects (n = 17). Samples were further assessed for the presence and levels of fecal and serum secretory IgA (sIgA), proinflammatory proteins, and fatty acids. Results The gut microbiota observed in patients with PsA and patients with skin psoriasis was less diverse when compared to that in healthy controls. This could be attributed to the reduced presence of several taxa. Samples from both patient groups showed a relative decrease in abundance of Coprococcus species, while samples from PsA patients were also characterized by a significant reduction in Akkermansia, Ruminococcus, and Pseudobutyrivibrio. Supernatants of fecal samples from PsA patients revealed an increase in sIgA levels and decrease in RANKL levels. Analysis of fatty acids revealed low fecal quantities of hexanoate and heptanoate in both patients with PsA and patients with psoriasis. Conclusion Patients with PsA and patients with skin psoriasis had a lower relative abundance of multiple intestinal bacteria. Although some genera were concomitantly decreased in both conditions, PsA samples had a lower abundance of reportedly beneficial taxa. This gut microbiota profile in PsA was similar to that previously described in patients with inflammatory bowel disease and was associated with changes in specific inflammatory proteins unique to this group, and distinct from that in patients with skin psoriasis and healthy controls. Thus, the role of the gut microbiome in the continuum of psoriasis–PsA pathogenesis and the associated immune response merits further study. Research is published: http://onlinelibrary.wiley.com/doi/10.1002/art.38892/full
Institute
University of Michigan
DepartmentBiomedical Research Core Facilities
LaboratoryMetabolomics core
Last NameKachman
First NameMaureen
Address6300 Brehm Tower, 1000 Wall Street, Ann Arbor, MI 48105-5714
Email mkachman@umich.edu
Submit Date2015-06-08
Num Groups4
Total Subjects89
Raw Data AvailableYes
Raw Data File Type(s)d
Uploaded File Size16 M
Analysis Type DetailGC-MS
Release Date2015-12-28
Release Version1
Maureen Kachman Maureen Kachman
https://dx.doi.org/10.21228/M8JG6Z
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR000160
Project DOI:doi: 10.21228/M8JG6Z
Project Title:Hirschprung Associated Enterocolitis Studies
Project Summary:Assess for correlations between SCFA content and history of HAEC
Institute:University of Michigan
Department:Surgery
Laboratory:Teitelbaum Lab
Last Name:Teitelbaum
First Name:Daniel
Address:Ann Arbor, MI
Email:dttbm@umich.edu
Phone:734-936-8464

Subject:

Subject ID:SU000237
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Mammals

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Disease Group
SA010619S00013315HLT
SA010620S00013314HLT
SA010621S00013313HLT
SA010622S00013316HLT
SA010623S00013318HLT
SA010624S00013304HLT
SA010625S00013319HLT
SA010626S00013312HLT
SA010627S00013317HLT
SA010628S00013305HLT
SA010629S00013311HLT
SA010630S00013307HLT
SA010631S00013306HLT
SA010632S00013309HLT
SA010633S00013310HLT
SA010634S00013308HLT
SA010635S00013375NORA
SA010636S00013374NORA
SA010637S00013376NORA
SA010638S00013377NORA
SA010639S00013373NORA
SA010640S00013378NORA
SA010641S00013369NORA
SA010642S00013379NORA
SA010643S00013368NORA
SA010644S00013370NORA
SA010645S00013371NORA
SA010646S00013372NORA
SA010647S00013383NORA
SA010648S00013389NORA
SA010649S00013388NORA
SA010650S00013390NORA
SA010651S00013380NORA
SA010652S00013392NORA
SA010653S00013387NORA
SA010654S00013391NORA
SA010655S00013381NORA
SA010656S00013386NORA
SA010657S00013382NORA
SA010658S00013384NORA
SA010659S00013385NORA
SA010660S00013361Ps
SA010661S00013360Ps
SA010662S00013362Ps
SA010663S00013359Ps
SA010664S00013358Ps
SA010665S00013365Ps
SA010666S00013357Ps
SA010667S00013367Ps
SA010668S00013366Ps
SA010669S00013364Ps
SA010670S00013363Ps
SA010671S00013348Ps
SA010672S00013347Ps
SA010673S00013349Ps
SA010674S00013346Ps
SA010675S00013345Ps
SA010676S00013356Ps
SA010677S00013350Ps
SA010678S00013344Ps
SA010679S00013351Ps
SA010680S00013355Ps
SA010681S00013354Ps
SA010682S00013352Ps
SA010683S00013353Ps
SA010684S00013327PsA
SA010685S00013326PsA
SA010686S00013329PsA
SA010687S00013330PsA
SA010688S00013325PsA
SA010689S00013328PsA
SA010690S00013323PsA
SA010691S00013331PsA
SA010692S00013320PsA
SA010693S00013321PsA
SA010694S00013322PsA
SA010695S00013324PsA
SA010696S00013338PsA
SA010697S00013340PsA
SA010698S00013341PsA
SA010699S00013342PsA
SA010700S00013343PsA
SA010701S00013339PsA
SA010702S00013337PsA
SA010703S00013333PsA
SA010704S00013334PsA
SA010705S00013335PsA
SA010706S00013336PsA
SA010707S00013332PsA
Showing results 1 to 89 of 89

Collection:

Collection ID:CO000225
Collection Summary:-
Sample Type:Feces

Treatment:

Treatment ID:TR000245

Sample Preparation:

Sampleprep ID:SP000239
Sampleprep Summary:-
Sampleprep Protocol Filename:SCFA_analysis_protocol-2015-03-10.docx

Combined analysis:

Analysis ID AN000322
Analysis type MS
Chromatography type GC
Chromatography system
Column Phenomenex Zebron ZB-WAXplus (30m x 0.25mm,0.25um)
MS Type EI
MS instrument type Single quadrupole
MS instrument name Agilent 5975C
Ion Mode POSITIVE
Units pmol/mg sample dry weight

Chromatography:

Chromatography ID:CH000243
Methods ID:AQM030
Methods Filename:WAXPLUS_100-200C_2_SIM.M.txt
Column Name:Phenomenex Zebron ZB-WAXplus (30m x 0.25mm,0.25um)
Chromatography Type:GC

MS:

MS ID:MS000271
Analysis ID:AN000322
Instrument Name:Agilent 5975C
Instrument Type:Single quadrupole
MS Type:EI
Ion Mode:POSITIVE
Acquisition Parameters File:WAXPLUS_100-200C_2_SIM.M.txt
Processing Parameters File:EX00263-SCFA-Quant-methods.m.zip
  logo